(131)I-MIBG, (90)Y-DOTATATE or (177)Lu-DOTATATE in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.

Trial Profile

(131)I-MIBG, (90)Y-DOTATATE or (177)Lu-DOTATATE in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs 90Y DOTATATE (Primary) ; Iobenguane (Primary) ; Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Paraganglioma; Pheochromocytoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top